Document is current
Any future updates will be listed below
-
Authors
Xander, Nicolas S. H. https://orcid.org/0000-0001-8252-6177
Belleman, Tom https://orcid.org/0000-0002-9086-6558
Salcher-Konrad, Maximilian https://orcid.org/0000-0002-5628-5266
Hendrickx, Anne https://orcid.org/0000-0001-5433-3650
Chen, Jeffrey
Klein Gebbink, Anne-Sophie
Schneider, Peter https://orcid.org/0000-0003-2113-0368
Morgan, Kate
Groene, Oliver https://orcid.org/0000-0002-1099-2950
Durand-Zaleski, Isabelle https://orcid.org/0000-0002-4078-1476
Thielen, Frederick W. https://orcid.org/0000-0002-0312-5891
Uyl-de Groot, Carin A. https://orcid.org/0000-0001-5808-302X
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Health (101094938)
- License Information
-
More Information
Article History
Received: 10 January 2025
Accepted: 6 August 2025
First Online: 6 September 2025
Declarations
:
: The authors have no competing interests to declare that are relevant to the content of this article. Maximilian Salcher-Konrad reports receiving nonfinancial support from Medicines for Europe (travel and accommodation fees for attendance at a conference) outside the submitted work. Kate Morgan has no personal conflicts of interest, but Myeloma Patients Europe received funding from the following companies in 2023 and 2024: AbbVie, Amgen, Alexion, AstraZeneca, BeiGene, Binding Site, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Kite, A Gilead Company, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Menarini Stemline, Takeda, Sebia, Prothena, SkylineDx, and Sandoz. Frederick Thielen resports that previous and ongoing research he was involved in was or is partly funded by Celgene B.V., NICE (UK National Institute for Health and Care Excellence), CADTH (Canadian Agency for Drugs and Technologies in Health), the Dutch Ministry of Health, Welfare and Sport, the Dutch Health Care Institute, and the European Haematology Association.
